Related and unrelated donor transplantation for β-thalassemia major: Results of an international survey

Westudied 1110 patients with b-thalassemia major aged ≤25 years who received transplants with grafts from HLA-matched related (n 5 677; 61%), HLA-mismatched related (n 5 78; 7%), HLA-matched unrelated (n 5 252; 23%), and HLA-mismatched unrelated (n 5 103; 9%) donors between 2000 and 2016. Ninety percent of transplants were performed in the last decade. Eight-five percent of patients received ≥20 transfusions and 88% were inadequately chelated. All patients received myeloablative-conditioning regimen. Overall and event-free survival were highest for patients aged ≤6 years and after HLA-matched related and HLA-matched unrelated donor transplantation. The 5-year probabilities of overall survival for patients aged ≤6 years, 7 to 15 years, and 16 to 25 years, adjusted for donor type and conditioning regimen were 90%, 84%, and 63%, respectively (P <001). The corresponding probabilities for event-free survival were 86%, 80%, and 63% (P <.001). Overall and eventfree survival did not differ between HLA-matched related and HLA-matched unrelated donor transplantation (89% vs 87% and 86% vs 82%, respectively). Corresponding probabilities after mismatched related and mismatched unrelated donor transplantation were 73% vs 83% and 70% vs 78%. In conclusion, if transplantation is considered as a treatment option it should be offered early (age ≤6 years). An HLA-matched unrelated donor is a suitable alternative if an HLA-matched relative is not available.